Li Ning (Junshi)
A 'breakthrough' PD-1? From China? FDA says why not for rare cancer
PD-(L)1 inhibitors may be the standard of care and the cornerstone therapy for a number of cancers, but in other niches, the FDA is still …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
